



and R_2 is selected from the group consisting of H and 3- CONH_2 , and n is an integer between 8 and 10.

48. (New) The amphiphilic pyridinium compound of Claim 47, wherein R_1 is




and R_2 is H, and n is 8.

49. (New) The amphiphilic pyridinium compound of Claim 47, wherein R_1 is




and R_2 is H, and n is 8.

50. (New) The amphiphilic pyridinium compound of Claim 47, wherein R_1 is




and R_2 is H, and n is 10.

51. (New) The amphiphilic pyridinium compound of Claim 47, wherein R_1 is




and R_2 is H, and n is 8.

52. (New) The amphiphilic pyridinium compound of Claim 47, wherein R_1 is




and R_2 is H, and n is 8.

53. (New) The amphiphilic pyridinium compound of Claim 47, wherein R_1 is




and R_2 is H, and n is 8.

54. (New) The amphiphilic pyridinium compound of Claim 47, wherein R_1 is




and R_2 is 3-CONH₂, and n is 8.

55. (New) The amphiphilic pyridinium compound of Claim 47, wherein R_1 is




and R_2 is H, and n is 8.

56. (New) An amphiphilic pyridinium compound having a structure:




wherein R_1 is selected from the group consisting of:




and R_2 is selected from the group consisting of H and 3-CONH₂, and n is an integer between 8 and 10.

57. (New) A pharmaceutical composition comprising an amphiphilic pyridinium compound of claim 56, and a pharmaceutically acceptable carrier.

58. (New) The pharmaceutical composition of claim 57, wherein said amphiphilic pyridinium compound is



59. (New) The pharmaceutical composition of claim 57, wherein said amphiphilic pyridinium compound is



60. (New) The pharmaceutical composition of claim 57, wherein said amphiphilic pyridinium compound is

